Abstract
BackgroundITIL–306 is a genetically engineered autologous TIL cell therapy that amplifies TCR–specific antigen recognition (Signal 1) with an FRα-specific CoStimulatory Antigen Receptor (CoStAR; Signal 2).1 T-cell activation through the endogenous...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
